Close Menu
Home » Illumina

Illumina

Illumina is a developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function. Illumina has developed a line of DNA sequencing technology products that address the scale of experimentation and breadth of functional analysis to advance disease research, drug development, and the development of molecular tests.

Illumina Company Profile 

 

President & CEO: Francis deSouza

CEO photo:

illumina CEO Francis deSouza photo

Website: www.illumina.com

Ticker symbol: ILMN

Headquarters: San Diego, CA

Illumina employees: 5,500+ globally

Revenues: $2.4 Billion USD in 2016

Founded: 1998

Founders: Larry Bock, Anthony Czarnik, David Walt, Mark Chee, John Stuelpnagel

 

Illumina News 

Mar 21, 2019

Illumina-Sponsored Study Finds Liquid Biopsy Complements Tissue-Based Genotyping in Lung Cancer

The study adds to growing evidence around the utility of cell-free DNA testing in lung cancer patients, while highlighting shortcomings of the approach.

Mar 12, 2019

Forensic Genomics Firm Othram Raises $4M

The company also said it has been awarded a research sequencing grant from Illumina Accelerator.

Mar 06, 2019

Illumina, Chinese Firm Partner on NGS System for Genetic Disease Dx

The companies will develop an IVD system based on the MiniSeq initially to diagnose hereditary kidney disease.

Feb 27, 2019

Genome Sequencing Rarely Leads to Lifestyle Changes in Healthy Individuals, Early Study Results Show

The Personal Genome Sequencing Outcomes (PeopleSeq) Consortium surveyed more than 500 early adopters who underwent personal genome or exome sequencing.

Feb 20, 2019

To Know What's Wrong

A new study finds that the majority of patients at a Tijuana clinic received a diagnosis after first-line genome sequencing, the San Diego Union-Tribune reports.

Feb 08, 2019

Illumina Details NCI Effort to Validate NGS Oncology Panel for Liquid Biopsies

Premium

The effort will also help resolve open questions about liquid biopsy sequencing's validity in clinical practice in general.

Feb 01, 2019

NanoString Leads January GenomeWeb Index as News From JP Morgan Conference Bolsters Stocks

The index, which outperformed the Dow Jones and the Nasdaq this month, gained 11 percent and rebounded from its 11 percent loss in December.

Feb 01, 2019

PacBio Settles Suits With Investors

PacBio agreed to pay attorneys' fees to settle lawsuits brought against it by investors regarding Illumina's acquisition.

Jan 30, 2019

Illumina Expands Clinical Business Internationally; Discounts NovaSeq Flow Cells

Premium

Illumina continues to forge partnerships with diagnostic developers overseas as it eyes approximately 50 population sequencing projects around the world.

Jan 29, 2019

Illumina Q4 Revenues Rise 11 Percent; Full Year Revenues Up 21 Percent

The company said that the revenue increase has been driven by growth in its sequencing business, particularly as genomics moves into the clinic.

Pages

The Scan

Concerns About Bias in Policies

Researchers representing scientists and students of Chinese descent voice their concerns about recent US policies and rhetoric.

Reprogrammable DNA

Wired reports that researchers have shown they could reprogram a DNA-based computer.

Lack of Diversity

Researchers say increased diversity in genomic studies will benefit all, PBS NewsHour reports.

This Week in Science

In Science this week: whole-genome sequencing of single sperm cells, and more.

What's Popular?

In Illumina

  1. Illumina-Sponsored Study Finds Liquid Biopsy Complements Tissue-Based Genotyping in Lung Cancer

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb LLC.  All Rights Reserved.